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in Asthma
Chris J Corrigan1 and Tak H Lee1
ABSTRACT
In the past decade it has become clear that asthmatic patients who are clinically unresponsive, or “resistant” to
glucocorticoid therapy may have T cells which manifest resistance to glucocorticoid inhibition. This is shown by
failure of glucocorticoid not only to repress the production of pro-inflammatory, asthma-relevant cytokines such
as IL-5, but also to induce the production of anti-inflammatory cytokines, such as IL-10. Molecular mechanisms
underlying this resistance are beginning to be defined, and include inappropriate production of transcriptional
regulatory proteins (which may bind to and inactivate the glucocorticoid receptor), cytokine-induced modifica-
tions of the glucocorticoid receptor (such as phosphorylation), which alter its capacity to bind to ligand, and
complex interactions which regulate histone acetylation status and the quaternary structure of DNA itself. Con-
tinued study of these phenomena will lead to a better understanding of the “normal” physiological mechanisms
of glucocorticoid action, and may point to new, alternative avenues of therapy for glucocorticoid resistant asth-
matics who suffer from severe disease, and for whom as yet no adequate therapy is available．
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INTRODUCTION
Glucocorticoids are very effective therapy for asthma
and numerous studies have shown that they reduce
asthma symptoms, exacerbations and bronchial hy-
perresponsiveness. Unfortunately, however, a propor-
tion of patients develop severe disease which is rela-
tively or totally refractory to glucocorticoid therapy.
While the numbers of these patients are small, they
consume a significant proportion of medical re-
sources in terms of both time and money.1 Regard-
less of cost considerations, there is an urgent need to
provide alternative therapies for these patients, who
often have severely impaired quality of life not only
from the severity of their symptoms but from the ef-
fects of excessive glucocorticoid exposure.
THE CONCEPT OF GLUCOCORTICOID RE-
SISTANT ASTHMA
The diagnosis of glucocorticoid resistant asthma is
essentially one of exclusion. Before it can be diag-
nosed , it must be ensured that the diagnosis of
asthma is correct and that factors contributing to
poor asthma control have been eliminated as far as is
possible. These stages have been formalised2 as fol-
lows :
·Establishconfirm the diagnosis of asthma
·Ensure that adequate dosages of glucocorticoids
are reaching the airways (compliance, inhaler tech-
nique, metabolic factors which may increase gluco-
corticoid clearance)
·Exclude ongoing exposure to provoking agents
(smoke, irritants, allergens, etc.)
·Rule out and eliminate as far as possible other po-
tential aggravating conditions (chronic sinusitis, oe-
sophageal reflux , drugs which may exacerbate
asthma, etc.)
·Rationalise inhaled β2-agonist therapy
·Introduce a strict management plan to assess re-
sponse to therapy which will typically last for weeks
or sometimes months.
Even when all factors which may abrogate the ef-
fects of glucocorticoid therapy are eliminated or mini-
mised as far as possible, there remains a group of pa-
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tients who show little or no response of airways ob-
struction to glucocorticoid therapy. This concept was
first proposed nearly 30 years ago.3,4
The first attempt to define glucocorticoid resistant
asthma in objective terms5 was based on changes in
FEV1 following a 14 day course of oral prednisolone
( 40 mgday ) . Patients showing improvements of
<15% of baseline were classified as resistant, whereas
those showing improvements of 30% or more were
considered sensitive. All patients, in contrast, showed
marked improvement in FEV1 in response to inhaled
β2-agonists, indicating that, in both patient groups,
airways obstruction is potentially at least partly re-
versible. Clearly, these FEV1 responses represent op-
posite ends of a continuum of clinical response. Most
subsequent studies have employed definitions of glu-
cocorticoid sensitive and resistant asthma similar or
identical to the above, in both adults and children.6,7
The minimum necessary period of glucocorticoid
therapy required to detect a response has never been
formally defined. It is possible that 14 days may not
always be sufficient, although it was shown8 that 90%
of severe asthmatic children showing an improve-
ment in FEV1 >15% of baseline on high-dosage oral
glucocorticoid therapy did so within 10 days．
On the basis of these studies, a workshop of ex-
perts on glucocorticoid resistant asthma proposed
that this should be defined by the failure to improve
baseline morning pre-bronchodilator FEV1 by more
than 15% of the baseline value following at least 14
days of therapy with prednisolone 40 mg daily or its
equivalent.9 Patients with complete glucocorticoid re-
sistance show not only a failure of response in terms
of FEV1, but also, in general, an ability to tolerate re-
duction of glucocorticoid dosages without significant
change in disease activity. In addition, they typically
show little increase in FEV1 even with more pro-
tracted, much higher dosages of systemic glucocorti-
coids. This is in distinction to glucocorticoid “depend-
ent” asthmatics , who may not show a response in
FEV1 of 15% or more during a 14 day trial of systemic
glucocorticoid therapy, but rapidly deteriorate when
this therapy is withdrawn . Although glucocorticoid
resistant patients may show a degree of fixed airways
obstruction, many show marked diurnal variability in
PEF and a brisk bronchodilator response . 6,7 Most
clinical descriptions of glucocorticoid resistant
asthma emphasise the following common clinical fea-
tures10 :
·Persistent symptoms despite optimal therapy
·Chronic airflow limitation with FEV1 < 60% pre-
dicted in adults and <80% predicted in children
·Failure to achieve an increase in morning pre-
bronchodilator FEV1 of >60% predicted despite sys-
temic glucocorticoid therapy (at least 40 mgday of
prednisolone or its equivalent given for at least 14
days)
·Frequent nocturnal symptoms with significant
“morning dipping” of PEF
·Poor clinical and spirometric response to oral glu-
cocorticoid therapy, with <15% improvement in pre-
bronchodilator FEV1 following a trial of oral glucocor-
ticoid therapy as specified.
MECHANISMS OF GLUCOCORTICOID RE-
SISTANT ASTHMA
Despite several decades of usage of glucocorticoids
as anti-inflammatory agents, relatively little is known
about the precise mechanisms by which they amelio-
rate inflammatory diseases. This echoes the fact that
little is known about precisely how inflammatory
changes in the bronchial mucosa of asthmatics actu-
ally cause clinical symptoms. Glucocorticoids exert a
number of generalised anti-inflammatory activities ,
such as capillary vasoconstriction and reduction of
vascular permeability, which may be relevant to sup-
pression of inflammation however caused. There is
now abundant evidence (reviewed in11 ) that gluco-
corticoid therapy which results in amelioration of
asthma is associated with reduced activation of, and
synthesis of asthma-relevant cytokines by activated T
cells. For example, elevated percentages of periph-
eral blood CD4, but not CD8 T cells from patients
with exacerbation of asthma expressed mRNA encod-
ing IL-3, IL-5 and GM-CSF but not IL-2 and IFN-γ as
compared with controls.12 Spontaneous secretion of
the corresponding cytokines was also demonstrable
in these patients using an eosinophil survival-
prolonging assay. The percentages of CD4 T cells ex-
pressing mRNA encoding asthma-relevant cytokines,
as well as spontaneous secretion of these cytokines
was reduced in association with glucocorticoid ther-
apy and clinical improvement. In a double-blind, par-
allel group study,13 therapy of mild atopic asthmatics
with oral prednisolone, but not placebo, resulted in
clinical improvement associated with a reduction in
the percentages of BAL fluid cells expressing IL-5
and IL-4 and an increase in those expressing IFN-γ.
These and many other studies support the general
hypothesis that glucocorticoids exert their anti-
asthma effect at least partly by reducing the synthesis
of cytokines by T cells．
FUNCTIONAL T CELL ABNORMALITIES IN GLU-
COCORTICOID RESISTANT ASTHMA
A corollary of the above is that glucocorticoid resis-
tant asthma may at least partly reflect refractoriness
of T cells to glucocorticoid inhibition. A pioneering
study in this field14 showed that lectin-induced colony
formation in soft agar by peripheral blood T cells in
vitro (a measure of proliferation) was less susceptible
to glucocorticoid (methylprednisolone 10−8 M) inhibi-
tion in clinically glucocorticoid resistant, as compared
with sensitive asthmatics. This observation was fol-
lowed up with two reports from the author’s labora-
tory15,16 characterising peripheral blood T cells of glu-
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cocorticoid sensitive and resistant asthmatics . In
summary, it was demonstrated in these reports that
lectin-induced proliferation of peripheral blood T cells
was inhibited by dexamethasone at therapeutic con-
centrations in glucocorticoid sensitive, but not resis-
tant asthmatics. This resistance was not absolute but
relative , reflecting a shift in the concentration-
response curve for inhibition. In other words, T cells
from glucocorticoid resistant asthmatics can be inhib-
ited by glucocorticoids, but only at concentrations re-
quiring glucocorticoid dosages that most physicians
would not contemplate using for protracted periods in
clinical practice. Consistent with this, it was demon-
strated 16 that elevated percentages of peripheral
blood T cells expressed the activation markers in
CD25 and HLA-DR in glucocorticoid resistant , as
compared with sensitive asthmatics, suggesting per-
sistent T cell activation in the resistant patients de-
spite glucocorticoid therapy．
In glucocorticoid resistant asthmatics , clinical re-
sistance to therapy could not be accounted for by dif-
ferences in absorption and clearance of plasma pred-
nisolone derived from orally administered predni-
sone. We have subsequently shown17 that the inhibi-
tion of lectin-induced proliferation of peripheral blood
T cells from asthmatics by glucocorticoids in vitro is
reproducible both in the short term and when pa-
tients are re-tested after intervals of several months.
This suggests that the degree of glucocorticoid sensi-
tivity of peripheral blood T cells from asthmatics, and
by inference their clinical sensitivity to glucocorticoid
therapy, remains relatively constant, although there
is evidence (see below) that sensitivity in individual
patients may vary to some degree according to the
ongoing severity of their disease．
Glucocorticoid resistant asthmatics are not Addi-
sonian and do not have elevated plasma cortisol con-
centrations,15 suggesting that the impaired glucocor-
ticoid responsiveness observed in their peripheral
blood T cells is not a generalised, systemic phenome-
non. One possibility is that impaired T cell glucocorti-
coid responsiveness in asthma may be induced by the
action of pro-inflammatory cytokines within the local
environment of the inflammatory process. In this re-
gard, there exists evidence that the glucocorticoid re-
ceptor ligand binding affinity of peripheral blood T
cells in asthmatics may be altered in the short term
according to disease severity in vivo and by exposure
to cytokines in vitro. The glucocorticoid receptor
ligand binding affinities of peripheral blood T cells
from a group of poorly controlled asthmatics were re-
duced as compared with normal controls (median Kd
29.0 vs 8.0 nM) . Glucocorticoid therapy of these asth-
matics, which was accompanied by clinical improve-
ment, was associated with a significant increase in af-
finity of the T cell glucocorticoid receptors.18 In a de-
tailed study of glucocorticoid receptor binding in pe-
ripheral blood mononuclear cells from glucocorticoid
sensitive and resistant asthmatics, two distinct abnor-
malities were observed.19 The majority of the asth-
matics (15 out of 17) demonstrated a significantly re-
duced receptor binding affinity (mean Kd 42.1 nM) as
compared with sensitive patients (mean Kd 21.6 nM)
and normal controls (mean Kd 7.9 nM). This abnor-
mality was confined to T cells, reverted to normal af-
ter culture of the T cells in vitro for 48 hours, but
could be sustained by culture in the simultaneous
presence of high concentrations of IL-2 and IL-4. The
remaining two glucocorticoid resistant asthmatics
had abnormally low numbers of nuclear glucocorti-
coid receptors with normal binding affinity. This ab-
normality was not confined to T cells and was not in-
fluenced by the presence of exogenous cytokines. It
was further shown20 that this abnormality could be in-
duced by culture of peripheral blood T cells from nor-
mal donors with IL-2 and IL-4 in vitro, and that this in-
duction was associated with a reduced inhibitory ef-
fect of methylprednisolone on the proliferation of the
T cells induced by phorbol ester and ionomycin. A
similar effect of exogenous IL-13 alone was subse-
quently demonstrated in monocytes . 21 The physi-
ological significance of these relatively small changes
in ligand binding affinity of the glucocorticoid recep-
tor is difficult to assess, but clearly they may contrib-
ute to glucocorticoid refractoriness . Alternatively ,
they may represent an epiphenomenon reflecting
more fundamental changes in the glucocorticoid re-
ceptor of T cells on exposure to cytokines (see be-
low)．
There is some evidence for a differential effect of
glucocorticoids on T cells from sensitive and resistant
asthmatics in vivo. 22 In this study, bronchoalveolar
lavage was performed in glucocorticoid sensitive and
resistant asthmatics before and after a course of oral
prednisone, and expression by BAL cells of mRNA
encoding cytokines was measured by in situ hybridi-
sation. Whereas prednisone therapy of the glucocorti-
coid sensitive asthmatics was associated with reduc-
tions in the percentages of BAL cells expressing
mRNA encoding IL-4 and IL-5 and elevation of the
percentages of cells expressing mRNA encoding IFN-
γ, only a decrease in the percentages of cells express-
ing mRNA encoding IFN-γ was observed in associa-
tion with prednisone therapy of the glucocorticoid re-
sistant asthmatics . These data are compatible with
the hypothesis that glucocorticoids exert differential
effects on cytokine mRNA expression in T cells from
glucocorticoid sensitive and resistant asthmatics in
vivo.
Although glucocorticoids generally reduce inflam-
mation by inhibiting the production of pro-
inflammatory cytokines, one interesting facet of glu-
cocorticoid action, which is receiving increasing at-
tention, is their ability to increase the production of
the anti-inflammatory cytokine interleukin-10 (IL-10).
Studies in patients, initially in transplantation,23 and
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more recently in other conditions including asthma,24
have demonstrated that administration of glucocorti-
coids, intravenously or by inhalation, results in a sig-
nificant increase in systemic or local IL-10 synthesis.
Parallel studies from our own laboratories have
shown a concentration-dependent induction by gluco-
corticoids of T cell IL-10 expression in vitro.25 Inter-
est in the possible therapeutic benefit of IL-10 in
asthma already exists, based on its proposed role in
regulating immune homeostasis in the lung.26 IL-10
inhibits pro-inflammatory cytokine production, anti-
gen presentation, T cell activation and mast cell and
eosinophil function (reviewed in 27 ) . Furthermore ,
synthesis of IL-10 is deficient in the airways of asth-
matics as compared with controls , 28 and polymor-
phisms of the IL-10 gene leading to impaired expres-
sion of IL-10 are associated with a more severe dis-
ease phenotype . 29 We have recently described a
marked deficiency in the capacity of CD4+ T cells
from glucocorticoid resistant asthmatics to synthe-
sise IL-10 following in vitro stimulation in the pres-
ence of dexamethasone, as compared with sensitive
patients of equivalent disease severity . 30 Defining
new modalities of therapy, involving new drugs alone
or in combination with glucocorticoids,31 which over-
come this defect may restore essential anti-
inflammatory mechanisms that help limit asthmatic
inflammation．
MOLECULAR BASIS OF GLUCOCORTICOID AC-
TION AND RESISTANCE
Recent observations have increased our knowledge
of how the GR regulates transcription, and how this
process may be modified both in vitro and in vivo.
The GR comprises of three domains, the N-terminal
or immunogenicity domain, the central DNA-binding
domain and the C-terminal ligand-binding domain.32
The GR in its ligand-unbound state is located primar-
ily in the cytoplasm as part of hetero-oligomeric com-
plexes containing the heat shock proteins 90, 70 and
50. Upon binding to ligand, the GR undergoes confor-
mational changes, dissociates from the heat shock
proteins, homodimerises and translocates to the nu-
cleus. There, the ligand-activated GR may interact
with DNA sequences (glucocorticoid response ele-
ments ) or with other transcriptional regulators
through proteinprotein interactions, directly influ-
encing the activity of the latter on their target genes．
Proteins which may bind directly to the GR and al-
ter its activity in this way include AP-1, NFκB, signal
transduction and activators of transcription (STATs)
and certain of the CCAAT-enhancer binding proteins
(CEBP). These interactions appear to be particularly
important in glucocorticoid-mediated suppression of
inflammation , and may allow the activated GR to
transrepress expression of cytokine genes without
binding to DNA at all.33
Interaction of GR with AP-1 ： The pro-
inflammatory transcriptional element activator
protein-1 (AP-1) is an important contributor to the ex-
pression of the asthma-relevant Th2 cytokines IL-4,
IL-5 and IL-13. AP-1 comprises of variable het-
erodimers of Jun (c-Jun, JunB and JunD) and Fos (c-
Fos, FosB, Fra1 and Fra2) family members. AP-1 is
inducible by a variety of cytokines and growth fac-
tors.34 It is activated through the phosphorylation of
c-Jun and the transcriptional regulation of c-Fos .
Phosphorylation of c-Jun is the end result of the ac-
tion of a trilayer of kinases.35 c-Jun itself is phospho-
rylated by Jun-N-terminal kinase (JNK), a member of
the extracellular signal-related kinasesmitogen-
activated protein kinases (ERKMAPK) family of ser-
inethreonine kinases. JNK is in turn activated by
phosphorylation by JNK kinase , a member of the
MAPKERK kinase (MEK) family of kinases that
phosphorylate on both a tyrosine and a threonine or
serine residue. Of the seven members of the MEK
family, MEK4 or Jun-N-terminal kinase kinase is prin-
cipally responsible for the phosphorylation of JNK. At
the top end of the trilayer, the most upstream kinases
in the cascade are the MEK kinases (MEKK), ser-
inethreonine kinases that are diverse in sequence
and structure．
We have implicated abnormal regulation of AP-1 in
the mechanism of glucocorticoid resistance.
Glucocorticoid-exposed peripheral blood mononu-
clear cells from glucocorticoid-resistant, as compared
with glucocorticoid-sensitive asthmatics had fewer ac-
tivated GR available for DNA binding,36 but elevated
DNA binding of AP-1 following phorbol ester stimula-
tion.37 These cells also demonstrated elevated basal,
as well as phorbol ester-stimulated, transcription and
translation of c-Fos . Furthermore , phorbol ester
stimulation of cells from glucocorticoid-sensitive pa-
tients induced a glucocorticoid-resistant phenotype,
which was associated with direct interaction between
the activated GR and c-Fos , detected by co-
immunoprecipitation.38 Binding of GR to other pro-
inflammatory transcriptional activators ( such as
CREB and NFκB ) was unaffected . We interpret
these data to suggest that mononuclear cells from
glucocorticoid-resistant asthmatics inappropriately
over-express AP-1, which sequesters and neutralises
activated GR , thus causing refractoriness to
glucocorticoid-induced inhibitory responses．
The role of p38 MAP kinase : p38 MAP kinase is an-
other member of the family of MAPKERK mole-
cules . Its activity is regulated by phosphorylation ,
principally by the p 38 MAP kinases MEK 3 and
MEK6. A recent study39 has raised the intriguing pos-
sibility that changes in the binding affinity of nuclear
GR induced by exposure to IL-2IL-4 may be caused
by direct phosphorylation of the GR at serine 226 sec-
ondary to the resulting activation of p38 MAP kinase.
Although this study did not directly demonstrate that
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p38 MAP kinase phosphorylation of the GR is respon-
sible for its reduced binding affinity for glucocorti-
coids or its defective induction of an inhibitory signal,
the hypothesis is certainly plausible. Similarly TNF-α
has been shown to induce glucocorticoid resistance
in normal human monocytes, possibly through activa-
tion of p38 MAP kinase in addition to NF-κB.40 Sev-
eral other protein kinases, such as JNK, may also
modify activity of the GR in this way, either directly
or through phosphorylation of co-factor mole-
cules.41,42
The findings with p38 MAP kinase raise the possi-
bility that the small alteration in ligand binding affin-
ity of the nuclear GR induced by IL-2IL-4 exposure
is an epiphenomenon reflecting more fundamental al-
terations in the function of the GR brought about by
phosphorylation. This is in line with the fact that the
observed changes in ligand-binding affinity of the GR
are relatively small and of doubtful physiological sig-
nificance per se. Such a fundamental alteration in GR
function is also suggested by the fact that serine 226
is located in the N-terminal domain of the GR, remote
from the ligand-binding pocket which resides in the
C-terminal portion of the molecule . There is some
precedent for the possibility that remote regions of
the GR may mutually interact. For example, there are
two trans-activation domains , activation functions
(AF) 1 and 2, situated respectively in the immuno-
genic and DNA-binding domains of the GR, which co-
contribute to the full activity of the GR molecule on
its responsive promoters. Conceivably, phosphoryla-
tion at a remote site might effect such interactions.
Furthermore, both AF1 and AF2 interact with several
other nuclear proteins and protein complexes, such
as members of the p160 family and the co-activators
p300cyclic AMP-responsive element-binding protein
(CREB)-binding protein (CRP) 43 which can affect the
glucocorticoid-titration response of GR transactiva-
tion of its responsive promoters.44
The role of the GRβ -isoform：The β-isoform of the
GR is a splice variant of the “normal” GR, or GRα ,
situated in exon 9. The cDNA sequence up until this
point encodes a common region of 727 amino acids.
Thereafter , the GRα splice adds 50 amino acids
whereas the β isoform has only a further 15 residues.
The consequence of this alternative splice was shown
to be an inability of the β isoform to bind ligand.45
The structural basis for this has been clarified by the
recent crystallisation of the GR ligand-binding do-
main complexed with dexamethasone and a peptide
that was homologous to the GR interaction domain of
the co-activator TIF2.46
Artificial transfection of cells with GRβ can inhibit
GRα-mediated stimulation of gene expression . 47,48
The popular theory to explain this is that GRβ acts as
a dominant negative inhibitor of GRα activity (but see
reservations below). Physiological expression of GRβ
in neutrophils has been suggested as a possible
cause of their relative refractoriness to glucocorticoid
inhibition.49 Several studies suggest that GRβ may be
induced in cell lines to an extent sufficient to induce
glucocorticoid resistance by pro-inflammatory cytoki-
nes such as TNF-α,48 possibly reflecting the location
of a consensus NF-κB binding sequence in the 5-
flanking sequences of the GR gene. Furthermore, in-
creased GRβ immunoreactivity has been reported in
peripheral blood mononuclear cells and bronchoal-
veolar lavage cells from patients with glucocorticoid-
resistant asthma,50 although possible modulation of
expression in association with glucocorticoid therapy
was not explored. In studies from our own laboratory
using a model of tuberculin-induced cutaneous in-
flammation, we reported elevated expression of GRβ
immunoreactivity in inflammatory cells infiltrating
the skin lesions in glucocorticoid resistant, as com-
pared with sensitive asthmatics.51 Treatment of the
patients with systemic glucocorticoids was associated
with reduced GRα expression in the glucocorticoid
sensitive, but not the resistant patients.
Notwithstanding these observations , it seems
likely that there is much yet to be learned about the
possible functional role of GRβ. For example :
Effects of GRβ on transcriptional activation : In
terms of transcriptional activation, the classical role of
GRα is to bind ligand, to dimerise and then to bind to
GRE. This binding permits the recruitment of co-
activator complexes , because one of the conse-
quences of ligand binding for nuclear hormone recep-
tors is a reduction in their affinity for co-repressor
complexes, and replacement of these complexes with
co-activators . The crystallisation data referred to
above46 indicate that GRβ lacks residues forming the
charge clamp required for docking of the amino ter-
minus TIF2 LXXLL motif, suggesting that GRβ may
be unable to recruit co-factors required for transcrip-
tional activation. Thus GRβ, by displacing GRα, could
conceivably act as a dominant negative inhibitor of
transcriptional activation. There are, however, uncer-
tainties regarding this conclusion. In the first place,
GRβ seems to be expressed in much lower quanti-
ties : (typically 10- to 100-fold less, at least at the level
of mRNA expression) : than GRα . In the second
place, whereas in the case of GRα ligand binding ap-
pears to be a prerequisite for nuclear translocation, it
is not known what governs the cytoplasmicnuclear
partitioning of GRβ or if it is present in sufficient
quantities in the cellular nucleus. Finally, it is unlikely
that GRβ could dimerise efficiently, so that its ability
to compete for binding with high affinity to GREs is
questionable．
Effects of GRβ on transcriptional repression : Re-
pression mediated by ligand bound GR is thought to
occur through binding to atypical sites on DNA, for
example non-consensus NFATAP-1 sites , rather
than binding to GREs. At these sites, it is thought
that the conformation of the DNA binding site, and
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the influence of locally bound factors might cause the
GR to adopt a structure that is not permissive for re-
cruitment of co-activators, but rather permissive for
recruitment of co-repressors. There is at present no
information as to whether or not GRβ can bind to
such sites and, more importantly, recruit co-repressor
complexes．
Inhibition of transcriptional activation mediated by
sequestration of transcription factors : So far, there has
been no clear demonstration for a role for the ex-
treme carboxy-terminus of the GR in the sequestra-
tion ( and inactivation ) of transcriptional activating
proteins such as AP-1. It is conceivable , therefore ,
that both GRα and GRβ could exert repressive effects
on gene expression by sequestration of such tran-
scriptional activators．
The possible role of histone proteins : DNA is pack-
aged into chromatin, a highly organised and dynamic
protein-DNA complex . The N-terminal tails of the
core histone proteins contain highly conserved lysine
residues that are sites for post-translational acetyla-
tion. Acetylation of histone residues results in un-
winding of the DNA coiled around the histone core.
This process opens up the chromatin structure, allow-
ing transcriptional factors and RNA polymerase II to
bind more readily to DNA, thereby increasing gene
transcription. 52 The large co-activator molecule
CREB binding protein (CBP) that binds to the basal
transcriptional apparatus has intrinsic histone acetyl
transferase (HAT) activity . Additionally , associated
co-activator proteins , including steroid receptor co-
activator-1 (SRC-1), transcription factor intermediary
factor-2 (TIF2), p300CBP co-integrator-associated
protein (pCIP) and glucocorticosteroid receptor en-
hancing protein-1 (GRIP-1) may enhance local HAT
activity. In genes which are induced by glucocorti-
coids, high concentrations of glucocorticoids cause
binding of the activated GR to CBP andor associated
co-activators , resulting in histone acetylation on ly-
sines 5 and 16 of histone H4 and increased gene tran-
scription. HAT activity may be further enhanced by
binding of transcriptional regulatory proteins such as
AP-1 and NF-κB . 52,53 Repression of genes is con-
versely associated with a reversal of this process by
histone deacetylation, mediated by histone deacety-
lases (HDACs).54 HDACs comprise of a growing fam-
ily of enzymes of which at least 10 mammalian mem-
bers have been described.55 Some, such as HDAC4
and HDAC8 are able to shuttle between the cellular
nucleus and cytoplasm. Histone acetylation is a dy-
namic process in which small changes in acetylase
and deacetylase activity can considerably alter the net
HAT activity at any particular gene promoter site .
Suppression of HAT activity, as well as recruitment of
HDAC activity to active transcriptional complexes
may play a role in glucocorticoid regulation of gene
transcription.56 This may occur in a variety of ways.
Glucocorticoid repression may reflect competition be-
tween the activated GR and the binding sites on CBP
for other transcriptional activating proteins, such as
AP-1,57 NF-κB, Sp1, Ets, NF-AT and STATs, which
may alter local HAT activity. Alternatively, and not ex-
clusively , the GR may bind to one of several co-
repressor molecules such as RIP140, NCoR1 and
GRIP1 which in turn associate with proteins having
differing HAT activity.58 These complex interactions
probably play a major role in the genesis of the infi-
nitely variable and subtle effects of glucocorticoids on
individual target cells.
Clearly, then, intrinsic abnormalities of, or external
influences on the regulation of HAT activity in indi-
vidual cells may influence their glucocorticoid re-
sponsiveness. Already there are suggestions that ex-
ternal influences such as exposure to cigarette
smoke , an oxidative stress , may inhibit the anti-
inflammatory actions of glucocorticoids on cells in
the lungs of smokers by reducing HDAC expression
and activity.59 Similar phenomena may contribute to
glucocorticoid resistance in asthma.
GENETIC BASIS OF GLUCOCORTICOID RESIS-
TANCE
The glucocorticoid receptor gene itself is a plausible
candidate for a genetic basis to glucocorticoid resis-
tance. A mis-sense mutation in this gene had previ-
ously been found to be responsible for the phenome-
non of familial glucocorticoid resistance.60 These pa-
tients have a markedly reduced affinity of the gluco-
corticoid receptor for ligand and clinically have fea-
tures of Addison’s disease, which is not the case with
glucocorticoid resistant asthmatics . Analysis of the
sequence of the glucocorticoid receptor protein in six
resistant and sensitive patients showed no mutations
in any of the subjects.61 Despite these observations, a
growing number of single nucleotide polymorphisms
(SNPs) are being described in the glucocorticoid re-
ceptor gene and its flanking sequences, which may
have functional consequences. Although this work is
ongoing, there is no obvious mutation that might ac-
count for glucocorticoid resistance. Obviously, rele-
vant mutations do not necessarily have to be within
the coding region of the receptor gene itself , but
could be in genes encoding products in downstream
signalling pathways．
In addition to this, glucocorticoid responsiveness
may be governed at least partly by genetic factors.
For example, one study suggested that inherited ab-
normalities might render approximately 7% of the
normal population relatively hypersensitive to gluco-
corticoids.62 Such influences may reflect genetic vari-
ability in the responses of a potentially vast number of
genes to glucocorticoids, including genes concerned
with airways remodelling, genes encoding chemoki-
nes and cytokines and their receptors and genes en-
coding signalling pathways downstream for receptors
for glucocorticoids or other anti-asthma drugs.63
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MANAGEMENT OF GLUCOCORTICOID RE-
SISTANT ASTHMA
Generally all patients with severe asthma, particularly
those admitted as an emergency will be treated with
systemic glucocorticoids at high dosage for at least
two weeks. It is only in the fullness of time that a pat-
tern of glucocorticoid responsiveness is established.
In patients thought to be truly glucocorticoid resis-
tant (that is, patients showing the proscribed failure
in FEV1 response when the diagnosis is confirmed
and aggravating conditions excluded), further long-
term therapy with systemic glucocorticoids is prob-
ably inadvisable since there is little evidence that
these drugs will influence asthmatic symptoms and
disease activity , but may on the other hand cause
considerable unwanted effects. In such cases it may
be sensible to reduce or withdraw glucocorticoids
and treat instead with adequate dosages of alternative
anti-asthma drugs such as bronchodilators , leukot-
riene receptor antagonists and immunosuppressive
drugs (see below). In clinical practice, however, be-
cause there is little hard evidence to justify with-
drawal of systemic glucocorticoids from any severe
asthmatic patient, this process is often ignored or de-
layed. In view of the possibility that glucocorticoid
sensitivity may change with time, it would seem pru-
dent to re-assess glucocorticoid sensitivity periodi-
cally64 although, as discussed above, within individu-
als T cell glucocorticoid sensitivity appears to be rela-
tively stable at least over a period of months.
The observation that glucocorticoid responsive-
ness of asthmatics correlates with glucocorticoid inhi-
bition of their T cells suggests that other drugs that
inhibit T cells might be useful for asthma therapy, in
particular drugs that inhibit T cells by mechanisms
distinct from those of glucocorticoids . We have
shown 16,17 that the immunosuppressive drugs cy-
closporin A, rapamycin and mycophenolate mofetil in-
hibit proliferation of T cells from glucocorticoid sensi-
tive and resistant asthmatics to an equivalent extent.
It has been shown65,66 that cyclosporin A, when ad-
ministered to patients with poorly controlled asthma
despite continuous systemic glucocorticoid therapy,
improved lung function while allowing reduction of
oral glucocorticoid dosages in a proportion of the pa-
tients . Similarly concomitant therapy of glucocorti-
coid dependent asthmatics with methotrexate 67 or
gold salts68 has been shown in some trials to spare
glucocorticoid therapy, although no trials have sug-
gested that these agents improve lung function. In
general, none of these agents is particularly satisfac-
tory in the sense that many patients fail to respond
and it is impossible to predict responsiveness a priori.
Furthermore, chronic immunosuppression raises the
risk of development of serious infection or malig-
nancy, and there is in addition a list of not insignifi-
cant unwanted effects associated, in some patients ,
with the use of each particular drug. An urgent ap-
praisal of other immunosuppressive drugs is needed
in glucocorticoid dependent and glucocorticoid resis-
tant asthma. It is a priority to produce a global defini-
tion of which patients are suitable for treatment, and
what constitutes an adequate trial of therapy.
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